espite the transformative potential of cell and gene therapies, widespread adoption remains limited due to systemic gaps in infrastructure, reimbursement models, and coordination of care.

In this report, you’ll learn from experts commenting on key challenges and emerging solutions within this space, including how cell gene therapies are revolutionizing patient care while creating new challenges for us as an industry.

In a Q&A with Jeff Casberg, MS, RPh, senior vice president of clinical pharmacy services at IPD Analytics, Casberg explains the evolution of specialty drugs, the future of GLP-1 competition and what to expect from the traditional drug pipeline.

Journavx is seeing strong initial market adoption, with growing payer coverage and ongoing clinical studies aimed at expanding its use

On this special episode of Not So Different honoring Global Biosimilars Week, Craig Burton, executive director of the Biosimilars...

Biologics are regulated by the FDA and are approved under the 351(a) pathway with a Biologics License Application (BLA).

An ICER review of eculizumab and efgartigimod for Myasthenia Gravis expressed serious concerns about drug pricing.

Authorized biologics are on the horizon and their release will likely coincide with the arrival of the first interchangeable biosimilar.

Competitors in the field of adalimumab and insulin products may soon include authorized biologics.

According to the IPD Analytics team, an adalimumab biosimilar launch may occur as early as late 2022.

Ernst and Young announced Howard Krass of IPD Analytics was named an Entrepreneur of the Year® 2020 Florida Award winner.

IPD Analytics experts discussed the impact of Covid-19 on the drug pipeline.

IPD Analytics experts discussed biosimilar competition on MJH Life Sciences News Network

With conversion of the BLA pathway, new launches may receive interchangeability. New insulin products are being launched in the near future

According to interviewed experts at IPD Analytics, the 2020 drug pipeline includes a large number of generic launches.

IPD Analytics discussed both the generic and biosimilar drugs coming to market, and implications for managed care pharmacy at AMCP eLearning

The pace of clinical trials have been affected by COVID-19, according to IPD Analytics' experts on the pharmaceutical pipeline.

There is some difference in opinion regarding how payers will set their formulary management strategy on GLP-1's.